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Background. Numerous randomized, controlled trials
have demonstrated that recombinant human erythropoietin
(rHuEPO, epoetin alfa) significantly raises hemoglobin levels,
reduces transfusion requirements, and improves quality of life
in anemic patients with chronic renal failure. However, this ac-
cumulation of data has yet to be systematically examined. The
objectives of this meta-analysis were to quantify the effects of
epoetin alfa on clinical efficacy, quality of life, hospitalizations,
and transfusions by collecting and analyzing the published body
of evidence.
Methods. Sixteen published studies fulfilled all inclusion cri-
teria and were subjected to data extraction. Data specifically
related to hemoglobin and/or hematocrit levels, quality-of-
life measurements, number and length of hospitalizations, and
number of blood transfusions were then pooled across studies
using a random effects meta-analysis. Simple combined esti-
mates of the preselected variables were calculated, and adjusted
estimates were made using meta-regression.
Results. Baseline hemoglobin levels (<8 g/dL) increased sub-
stantially (40% to 50%) after epoetin alfa administration to a
nonanemic state (Hb >11 g/dL) for the pooled study group.
Substantial improvements (10% to 70%) were observed for all
measures of quality of life. In addition, patients who received
epoetin alfa had substantial reductions in hospitalization rate,
hospital length of stay, transfusion rate, and number of units
transfused.
Conclusion. This meta-analysis strongly suggests that epoetin
alfa therapy for patients with chronic renal failure provides im-
portant clinical and quality-of-life benefits while substantially
reducing hospitalizations and transfusions.
Anemia is a nearly inevitable and potentially debilitat-
ing consequence of chronic renal failure [1]. Ordinarily,
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tissue hypoxia leads to an increased production of the
hormone erythropoietin within the kidney, which then
stimulates the division and differentiation of committed
erythroid progenitors in the bone marrow (erythro-
poiesis). The anemia of chronic renal failure results from
inadequate secretion of erythropoietin by the damaged
kidney in response to hypoxia. Erythropoietin deficiency
leads to diminished red blood cell counts and hemoglobin
levels, and lower overall oxygen availability [2]. The con-
sequences for patients include fatigue, loss of energy, and
an inability to carry out the activities of daily living, result-
ing in loss of economic productivity, poor quality-of-life,
and increased dependency on others [3].
Recombinant human erythropoietin (rHuEPO, epo-
etin alfa) has long been accepted as a clinically useful
therapy for anemia in patients with chronic renal fail-
ure, having been shown to increase hemoglobin levels
and decrease transfusion requirements [3–5]. Moreover,
published data from rigorous clinical trials, as well as
anecdotal reports from patients, indicate that epoetin alfa
therapy also provides substantial benefits in quality of life
[1, 6, 7]. The most immediate quality-of-life benefits of
epoetin alfa therapy described by chronic renal failure
patients with anemia appear to be increased energy and
resulting increased capacity to function.
Finding and analyzing all relevant therapeutic trials in
a given field has become a difficult and specialized task.
The systematic aggregation of data from multiple trials
using statistically rigorous techniques has thus become an
increasingly important aid to achieving meaningful con-
sensus. The meta-analysis reported here analyzes the
quantitative outcomes evidence for clinical efficacy, qual-
ity of life, hospitalizations (number and length of stay),
and transfusions (rate and number) to determine the
overall impact of these positive outcomes in patients with
chronic renal failure who receive epoetin alfa for anemia.
Our objective was to collect, document, and analyze all
available data on these variables, and to provide a clear
and comprehensive report on the effects of epoetin alfa
therapy for this patient population.
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METHODS
Literature search
A critical review of the literature was undertaken,
and the published quantitative data were collated and
quantitatively synthesized to form balance-of-evidence
estimates.
Experienced library staff in the medical library at The
Royal North Shore Hospital (Sydney, Australia) em-
ployed the Medline database to search for publications
relating to epoetin alfa therapy and chronic renal failure.
Search parameters included the impact of epoetin alfa
on chronic renal failure, with regard to hematocrit and
hemoglobin levels, survival, quality of life, hospital ad-
mission, transfusion rate, and cost. A combination of a
controlled subject heading search and a text/word search
was employed to achieve an appropriate trade-off be-
tween sensitivity (the likelihood of retrieving relevant
items) and specificity (the likelihood of excluding irrel-
evant items). The staff conducting the literature search
for this project regularly performs similar searches for
Cochrane groups and used comparable methods for the
current study.
Abstracts were sought only for those studies that fit the
prespecified inclusion criteria. Studies were included that:
(1) were published between 1985 and 2000; (2) enrolled
adult patients (≥18 years of age); (3) contained at least
20 patients per study arm; (4) recruited patients with a
diagnosis of chronic renal failure; (5) involved treatment
with epoetin alfa; and (6) reported on one or more of the
chosen variables pertaining to clinical efficacy, quality-
of-life, hospitalizations, and/or transfusions. English lan-
guage was not an inclusion criterion; articles in languages
other than English were translated by a qualified transla-
tion service.
A question that often arises in a literature search is
whether or not any relevant articles may have been
missed. Some confidence is gained, however, from the
fact that slightly over 1000 abstracts and close to 100 ar-
ticles in full were reviewed, and a considerable range of
journals and articles both in English and in several non-
English languages was examined.
Data extraction
An initial review of all articles identified as potentially
relevant from the abstract search was conducted to de-
termine which studies met the protocol-defined inclusion
criteria, and what pieces of data were sufficiently common
across publications to warrant extraction. A computer
database was then developed to accept the extracted data.
Data were extracted from each publication by two in-
dependent surveyors and entered onto a data extraction
form. The surveyors compared extractions and resolved
any discrepancies by jointly examining the publication.
The data were then entered into the database.
Measurements
All studies used in this meta-analysis were of the
“pre/post” design, in that measurements of anemia, qual-
ity of life, hospitalizations, and transfusions were taken
before and after initiation of epoetin alfa therapy, and
any changes in these variables were assumed to be at-
tributable to epoetin alfa. With very few exceptions, all
studies reported means and variance estimates pre- and
post-therapy; some also reported mean changes or vari-
ance estimates of change within subjects. In the former
case, it was necessary to calculate the variance estimates
of change, assuming independence of the pre- and post-
therapy measurements. The approximation method used
here works against epoetin alfa, because some of the
between-subject variance that is usually removed by cal-
culating pre- to post-therapy changes within each subject
remained. Thus, the residual variance was larger than it
ought to have been (if individual patient data were avail-
able), but the variance attributable to epoetin alfa was
not.
A few studies [3, 8, 9] included the means of pre- and
post-therapy measurements but lacked measures of vari-
ance. To avoid losing such data due to the missing vari-
ance estimates, standard errors were imputed, assuming
the standard deviation to be equal to the mean of known
standard deviations while using the study-specific sample
size in the calculation. This approach is the same used
by Birks et al [10] of the Cochrane Collaboration in their
meta-analyses discussing mild and moderate Alzheimer’s
disease, and rivastigmine therapy in Alzheimer’s disease
patients [11].
In accordance with the pre/post design of all stud-
ies included in this meta-analysis, the percentage of
patients who were hospitalized and/or received transfu-
sions, length of hospital stay; and number of blood units
transfused, were calculated both before and after initia-
tion of epoetin alfa therapy, with the exception of deaths.
The period over which these variables were recorded
generally ranged between 3 and 12 months. In order to
standardize the period at risk, all counts were scaled to co-
incide with a 6-month study period. In doing so, a uniform
rate of utilization was assumed (i.e., if 10 transfusions oc-
curred over a 12-month follow-up period, 5 transfusions
were assumed for a standard 6-month period).
Where utilization parameters (e.g., total units trans-
fused) were reported for the entire group rather than per
patient, the parameter was translated to a per-patient ba-
sis by dividing by the number of relevant subjects (e.g., by
the total number of transfused patients). The calculation
of standard errors for the transformed data assumed that
the resulting random variable followed a Poisson distri-
bution. When the sample size pertaining to a particular
parameter was unknown, the overall study sample size
was assumed.
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While epoetin alfa dose has generally been reported
as starting dose and final dose in the medical literature,
final dose was used for this meta-analysis. Where dosage
was reported as units/week rather than units/kg/week, an
average 70-kg patient was assumed and the dosage scaled
accordingly. In studies that reported dose as a frequency
of “three times weekly” or “each dialysis,” the dose was
multiplied by 3 in order to approximate a weekly dosage.
For analytic purposes, percentages for this meta-
analysis were transformed to the logit scale where
logit(p) = ln[p/(1−p)] and p is the proportion (per-
cent/100). To avoid undefined logits, a constant of 0.01
(1%) was added to all proportions before transforma-
tion and subtracted after the analysis. Logits have the de-
sirable properties of asymptotic normal distribution and
confidence interval boundaries for proportions that lie
within the range 0≤P≤1. All percentages of 100% were
limited to 99% in order to avoid numerically undefined
logits.
Quantitative data analysis
The quantitative analysis had two main components:
the formation of simple combined estimates of findings
across studies (test of homogeneity [positive result sig-
nifies heterogeneity]; significance at P < .05), and an
analysis of potential publication bias. The simple com-
bined estimates were formed using the DerSimonian and
Laird approach [12]. Demographic and clinical history
data were extracted, and variation between studies was
then analyzed in two primary ways: (1) stratification by
demographic and clinical characteristics followed by for-
mation of combined estimates within strata and com-
parison across strata; and (2) analysis of demographic,
clinical, and study design variables as sources of between-
study variance in meta-regression.
Analysis of publication bias was undertaken using the
test described by Egger et al [13], and through the cre-
ation of funnel plots. This statistical test amounts to a
nonparametric correlation of standardized effect size es-
timates correlated with their variances (significance at
P < .05).
Quality of life
Quality of life was evaluated using the Karnofsky Per-
formance Scale (KPS), the Kidney Diseases Question-
naire (KDQ), and the Sickness Impact Profile (SIP). The
KPS uses 10 steps with scores ranging from 100 (normal,
without any limitation) to 10 (moribund) as an overall
indicator of functional ability and self-sufficiency, and is
considered an objective quality-of-life indicator [14]. The
KDQ is specific for patients with end-stage renal disease
[15]. It contains 26 questions divided into five sections:
patient-specific physical symptoms; fatigue; depression;
relationships; and frustration. All questions are scored
on a 7-point Likert scale (7 = no problem, 1 = severe
problem). The SIP is a behavior-related questionnaire
that evaluates non-disease–specific, sickness-related be-
havioral dysfunction [16]. It is widely used for end-stage
renal disease patients and in studies evaluating quality-
of-life improvement with epoetin alfa treatment for end-
stage renal-disease–related anemia. The SIP includes 136
items grouped into 12 categories of activity in physical
and psychologic dimensions. Scores range from 0 (no be-
havioral dysfunction) to 100 (100% dysfunction in a cat-
egory or group). Unlike the KPS and the KDQ, lower
scores for the SIP indicate better quality of life.
RESULTS
Of the 95 articles that were obtained and assessed for
inclusion in this meta-analysis, 22 fulfilled all inclusion
criteria. Within this group, another six were determined
by the two surveyors to be of inappropriate experimental
design because they did not include pre- and post-epoetin
alfa therapy measurements.
Quantitative data were, therefore, extracted from a to-
tal of 16 published studies [3, 5, 7–9, 17–27]. Five studies
were randomized, controlled trials [5, 8, 24, 26, 27]. In
two of these 16 studies, epoetin alfa therapy was adminis-
tered to more than one study group. One study evaluated
low-dose versus high-dose epoetin alfa [8], and another
included both intravenous and subcutaneous administra-
tion [24]. In each of these studies, the two study arms
were treated as separate cohorts for this meta-analysis
and, hence, data were extracted from a total of 18 sepa-
rate cohorts (Table 1).
Demographic, clinical, and treatment characteristics
Among all 16 studies included in the quantitative anal-
ysis, patients averaged 50 years of age and were com-
prised of nearly equal proportions of men and women
(Table 2). Ninety-four percent of patients were receiv-
ing hemodialysis, 5% were in the predialysis category,
and the remaining 1% was undergoing peritoneal dial-
ysis. The majority of studies (61%) included the use of
supplemental iron. The dose of epoetin alfa was reported
generally as a group mean. Among the studies used in
this meta-analysis, the mean epoetin alfa starting dosage
of 209 U/kg/week was approximately 40% higher than
the final dosage of 142 U/kg/week. These data are based
on 15 cohorts at baseline and 11 cohorts post-therapy for
which dose/kg/week was reported or could be calculated.
Baseline
At baseline, the mean hemoglobin level across all avail-
able cohorts for this analysis was less than 8 g/dL, and
the mean hematocrit level was less than 30% (Table 3),
signifying that the “average patient” was anemic before
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Table 1. Graph identifications for primary papers used in meta-analysis
Graph ID Cohort analyzed N Design Authors
A1 Low-dose epoetin alfa 40 C Canadian Erythropoietin Study Group (1990)
A2 High-dose epoetin alfa 38 U
B All patientsa 23,806 (registry) Powe et al (1994)
C All patients 156 U Moreno et al (2000)
D All patients 28 U Harris et al (1991)
E All patients 22 U Auer et al (1992)
F All patients 60 U Stevens et al (1992)
G Epoetin alfa study armb 57 C Moreno et al (1996)
H Epoetin alfa study arm 42 C Kuriyama et al (1997)
I1 Intravenous epoetin alfa 38 C Muirhead, Churchill et al (1992)
I2 Subcutaneous epoetin alfa 45
J All patients 142 U Sundal et al (1991)
K All patients 37 U Duff et al (1991)
L All patients 98 U Muirhead, Laupacis et al (1992)
M All patients 58 U Paganini et al (1989)
N All patients 333 U Eschbach et al (1989)
O All patients 37 U Delano (1989)
P Epoetin alfa study arm 43 C Revicki et al (1995)
Abbreviations are: C, randomized controlled trial; ID, identification; U, uncontrolled trial.
a“All patients” for studies B-F and J-O indicates that the study was uncontrolled; all patients received epoetin alfa therapy, and, therefore, all data were extracted.
b“Epoetin alfa study arm” for studies G, H, and P indicates that the study was controlled, and, therefore, data were extracted only from the epoetin alfa arm of the trial.
Table 2. Demographic and clinical characteristics
Parameter Patients (N)/cohorts Mean or % 95% CI(lower–upper) Homogene
Age 47,695/14 51 48–55 <0.001
% female 47,719/15 49 45–53 0.001
% hemodialysis 48,207/18 94 87–97 <0.001
% peritoneal dialysis 48,207/18 1 0–4 <0.001
% iron usea NA 61 ± 12
Epoetin alfa dose, baseline U/kg/weekb NA 209 ± 206
Epoetin alfa dose, end U/kg/weekb NA 142 ± 70
NA is not applicable.
aPercentage ± standard error; data available for study sample as a whole, not individuals.
bMean ± standard deviation; data available for study sample as a whole, not individuals.
treatment administration. Additionally, patients’ quality
of life was poor, with all scores being either depressed
in the case of the KPS and the KDQ, or elevated in the
case of the SIP, indicating adverse quality of life. Over
one quarter of the patients required hospitalization be-
fore the onset of epoetin alfa therapy (Table 3). The mean
percentage of patients requiring transfusion at baseline
among the six cohorts for which that information was
available was 87.4%, a figure derived from heterogeneous
results, including one randomized controlled trial cohort
reporting 15%, and two randomized controlled trial co-
horts reporting 100%.
Response to therapy
Anemia. As shown in Table 4, mean hemoglobin in-
creased by >3 g/dL and hematocrit by >9% after the ad-
ministration of epoetin alfa. Figure 1 shows the individual
study findings for hemoglobin and hematocrit response
to epoetin alfa, along with the combined estimate, rep-
resented by a diamond at the bottom of the graph. The
study-specific mean increase in hemoglobin varied from
2 to 5 g/dL, and the mean increase in hematocrit from
5 to almost 15 percentage points among the studies. The
between-study variance was significant (P < 0.001), as
indicated by the test of homogeneity, but the effect of
therapy was always positive.
Quality of life. As shown in Table 4, quality of life
improved with epoetin alfa, as measured by increases in
the KPS and the KDQ and decreases in the SIP. These
results are also graphically displayed in Figures 2 and 3.
Mean change in KPS was 8.46 points, or approximately
11% of the average baseline score, a statistically signifi-
cant (P < 0.001) improvement in quality of life after epo-
etin alfa treatment. The physical and fatigue dimensions
of the KDQ showed mean increases of approximately
one point each, and the relationships and depression di-
mensions by approximately a half point each. These find-
ings are significant, because the confidence intervals of
the combined mean responses do not include the value
of zero (Table 4). The positive changes in the physi-
cal and fatigue dimensions represent increases between
15% and 30% from baseline, while the scores for the re-
lationships, depression, and global physical dimensions
increased between 10% and 15% from baseline. Corre-
sponding quality-of-life changes on the SIP were even
greater than those observed for the KDQ, with impact
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Table 3. Baseline conditions
Parameter Patients (N)/cohorts Mean 95% CI (lower−upper) Homogene
Hematopoietic
Hemoglobin g/dL 780/10 7.48 6.21–8.76 <0.001
Hematocrit % 772/9 24.32 21.11–27.53 <0.001
Quality-of-life
KPS 201/3 74.50 72.59–76.40 <0.001
KDQ: physical 200/5 4.11 3.82–4.41 0.01
KDQ: fatigue 200/5 4.29 4.10–4.49 0.7
KDQ: relationships 200/5 5.00 4.85–5.15 0.4
KDQ: depression 200/5 4.94 4.74–5.13 0.7
KDQ: frustration 200/5 4.90 4.61–5.19 0.08
KDQ: global physical 117/2 4.45 4.23–4.67 0.7
KDQ: global emotional 117/2 5.06 4.76–5.35 0.2
SIP: global 239/4 12.63 10.31–14.95 <0.001
SIP: physical 239/4 6.61 5.63–7.60 <0.001
SIP: psychologic 239/4 11.70 9.93–13.48 <0.001
Utilization parameters
Deaths % NA NA NA NA
Hospitalizations % 23,945/3 27.2 14.90–44.10 <0.001
Hospital daysa 12,889/3 9.02 5.62–12.42 0.4
Transfusions % 347/6 87.40 55.7–96.8 <0.001
Units transfusedb 347/3 5.5 0.8–10.3 0.04
Excluding Powe et al study [18]c
Hospitalizations % 139/2 21.7 10.9–37.9 0.01
Hospital daysa 34/2 7.72 3.87–11.58 0.9
Abbreviations are: KDQ, Kidney Disease Questionnaire; KPS, Karnofsky Performance Scale; SIP, Sickness Impact Profile; NA, not applicable/calculable.
aDays/hospital patient/6 months.
bUnits transfused/transfused patient/6 months.
cThe study conducted by Powe et al [18] is unique with respect to the other 15 trials included in the meta-analysis in that its data were derived from a pre-existing
database rather than from a newly designed clinical trial. If this study is removed from the analysis, the mean number of hospitalization days and the percentage of
patients hospitalized among those receiving epoetin alfa are reduced slightly from baseline.
Table 4. Response to epoetin alfa therapy (all trials)
P values
Outcome Patients (N)/cohorts Mean change 95% CI (lower−upper) Ha Bb
Hematopoietic
Hemoglobin g/dL 494/10 3.37 2.82–3.92 <.001 .04
Hematocrit % 493/8 9.10 7.31–10.89 <.001 .5
Quality of life
KPS 201/3 8.46 2.01–14.92 <.001 .5
KDQ: physical 164/5 1.16 0.88–1.44 .3 .8
KDQ: fatigue 164/5 0.80 0.52–1.09 .7 .4
KDQ: relationships 164/5 0.49 0.24–0.74 .6 .06
KDQ: depression 164/5 0.42 0.14–0.70 .9 .2
KDQ: frustration 164/5 0.21 −0.08–0.50 .9 .4
KDQ: global physical 81/2 0.65 0.31–0.99 .8 NA
KDQ: global emotional 81/2 0.29 −0.04–0.63 .6 NA
SIP: global 239/4 −5.17 −8.62–1.73 <.001 .4
SIP: physical 239/4 −3.29 −5.10–1.48 <.001 .4
SIP: psychologic 239/4 −7.86 −10.47–5.26 <.001 .4
Utilization parameters
Deaths % 1,136/13 3.3 2.2–4.7 .7 .5
Hospitalizations odds ratio 23,945/3 0.62 0.25–1.54 .006 .08
Hospital daysc 13,824/3 −3.59 −7.77–0.60 .5 .2
Transfusions % 247/4 0.03 0.00–0.24 <.001 .3
Units transfusedd 247/2 −2.6 −6.7–1.5 .2 NA
Excluding Powe et al study [18]e
Hospitalizations odds ratio 139/2 0.39 0.20–0.77 .9 NA
Hospital daysc 17/2 −4.46 −9.03–0.12 .4 NA
Abbreviations are: KDQ, Kidney Disease Questionnaire; KPS, Karnofsky Performance Scale; SIP, Sickness Impact Profile; NA, not applicable/calculable.
aTest of homogeneity; P < 0.05 = significant.
bPublication bias; P < 0.05 = significant.
cDays/hospital patient/6 months.
dUnits transfused/transfused patient/6 months.
eThe study conducted by Powe et al [18] is unique with respect to the other 15 trials included in the meta-analysis in that its data were derived from a preexisting
database rather than from a newly designed clinical trial. If this study is removed from the analysis, the mean number of hospitalization days and the percentage of
patients hospitalized among those receiving epoetin alfa are reduced slightly from baseline.
762 Jones et al: Meta-analysis of epoetin alfa in chronic renal failure
F:
C:
N:
D:
I2:
A1:
I1:
L:
A2:
E:
Combined
−25 −20 −15 −10 −5 0 5 10 15 20 25
A
Change in hemoglobin, g/dL
P:
C:
G:
H:
I2:
I1:
O:
N:
Combined
B
−5 0 5 10 15
Change in hematocrlt, %
Fig. 1. Effect of epoetin alfa therapy on hemoglobin (A) and
hematocrit (B) across individual studies. The center of the diamond
represents the combined mean response, while the tips of the diamond
represent the 95% CI. Individual cohorts are similarly labeled with
mean response and CI and are sorted by size of response.
scores typically reduced by half after the onset of epo-
etin alfa therapy. Quality-of-life responses to epoetin alfa
therapy, as measured by the SIP scale, suggest improve-
ments of approximately 50% or greater, depending on
the subscale analyzed.
Hospitalizations and transfusions. Administration of
epoetin alfa therapy substantially reduced the hospital-
ization rate (Table 4). Also, among those hospitalized,
length of stay within the hospital was reduced by over
3 days. The transfusion rate was nearly zero after starting
epoetin alfa therapy, and among patients who did receive
transfusion, the number of units transfused was reduced
by approximately 50%.
Figure 4 displays the impact of epoetin alfa on deaths,
hospitalizations, and transfusions. Note that each graph
in Figure 4 displays its response axis (x-axis) on a logarith-
mic scale. Taking log-odds ratios or logits of proportions
serves to linearize the scale and improve the resolution
for comparing studies. Although data points and/or odds
ratios for any one study are more challenging to iden-
tify from these logarithmic graphs, between-study relativ-
ities are enhanced in regard to interpretability. Increas-
ingly negative values for the logits of death indicate lower
death rates; similarly, a log-odds ratio less than zero in-
dicates a decrease in the likelihood of hospitalization or
transfusion after commencement of epoetin alfa therapy.
It was deemed appropriate to remove the Powe et al
study [18] from the analysis of hospitalization data, be-
cause this study does not present a stand-alone clinical
trial. Because the Powe et al study found greater-than-
average hospitalization rates in comparison to the other
studies, the omission of the study from this part of the
analysis made the reduction in the hospitalization rate
slightly more pronounced than that observed with its
inclusion.
Only one aspect of this analysis showed any substan-
tive evidence of potential publication bias; the Egger test
for publication bias for change in hemoglobin (P = .04;
Table 4) achieved statistical significance. At face value,
this would imply that the estimate for this parameter pre-
sented in Table 4 is biased (in either direction). However,
two factors qualitatively argue against this conclusion.
First, the P values reported take no account of the num-
ber of hypothesis tests conducted; hence, these could be
type I errors. In fact, any method of allowing for multi-
ple comparisons would reach this alternative conclusion.
Second, there is no suggestion that publication bias af-
fected the measurement of hematocrit level. If there were
publication bias operating, one would expect this bias to
apply consistently to hemoglobin and hematocrit levels,
because these two variables arise from the same measure-
ment domain and also demonstrate a nearly perfect pos-
itive correlation. In addition, graphs prepared of the bias
(not shown) suggest that the apparent bias in hemoglobin
change is the result of a single study (Eschbach et al [19])
with an extremely large standard error. This study also
stands out in Figure 1.
Between-study variance
While this meta-analysis clearly demonstrated that
epoetin alfa had a substantial and beneficial effect on
anemia associated with chronic renal failure, there was
considerable evidence of heterogeneity in the extent of
the benefit. Statistically significant (P < .05) between-
study heterogeneity was demonstrated for hemoglobin
and hematocrit levels, KPS, the SIP parameters, percent
of patients hospitalized, and percent of patients trans-
fused. For example, Figure 3 shows that, with respect to
the SIP, all studies yielded improvements in quality of life
after the initiation of epoetin alfa therapy, but that the de-
gree of improvement varied. The same situation is true
for the changes in transfusion and hospitalization rates
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Fig. 2. Effect of epoetin alfa therapy on qual-
ity of life as measured by the Karnofsky Per-
formance Scale (KPS) and the Kidney Dis-
ease Questionnaire (KDQ) across studies.
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Fig. 3. Effect of epoetin alfa therapy on qual-
ity of life, as measured by Sickness Impact
Profile (SIP) across studies.
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(Fig. 4); only one study with a very small positive odds
ratio indicated increased odds of hospitalization [18].
A sensitivity analysis was performed re-examining the
clinical response to epoetin alfa using only data from ran-
domized controlled trials. In the sensitivity analysis in-
cluding randomized controlled trials only, the mean and
95% CI results were similar to those arrived at by the
overall meta-analysis for most parameters (Table 5). Posi-
tive between-study heterogeneity was demonstrated only
for hemoglobin, hematocrit, and SIP: global.
Possible sources of between-study variation were in-
vestigated for all parameters for which statistically sig-
nificant between-study variation was reported in Table 4.
The factors considered as potential sources of variation
included patient, clinical, and study-design characteris-
tics, including year of publication, experimental design
(randomized, controlled trial vs. observational or natu-
ralistic study), treatment duration, mean disease dura-
tion, mean age, percentage of females in the sample, and
iron supplementation use (allowed vs. disallowed). The
independent factors found to have a statistically signif-
icant relationship with the change in a given parameter
Fig. 4. Mortality (A), hospitalizations (B), and transfusions (C) after
epoeitin alfa therapy.
are summarized in Table 6. The entries in parentheses
denote the direction of the relationship and the degree
of statistical significance (P value).
Fewer reductions were noted in the number of transfu-
sions for patients who received epoetin alfa among study
populations containing a greater proportion of older pa-
tients. In addition, the beneficial effect of epoetin alfa
in reducing transfusion requirement was diminished in
studies that allowed the use of supplemental iron.
Figure 5 indicates that later publications tended to re-
port a smaller hematologic benefit associated with epo-
etin alfa than earlier publications, showing a negative di-
rectional relationship with anemia and a clear, although
not consistent, reduction in the degree of change in hema-
tocrit with later year of publication.
DISCUSSION
Epoetin alfa has long been regarded as effective ther-
apy for anemia associated with chronic renal failure. Of
considerable interest are the quality-of-life benefits as-
sociated with increased hemoglobin and the impact of
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Table 5. Response to epoetin alfa therapy (randomized controlled trials only)
P values
Outcome Cohorts Mean change 95% CI (lower−upper) Ha
Hemoglobin g/dL 4 3.56 2.94–4.17 <0.001
Hematocrit % 4 8.14 5.63–10.65 <0.001
KPS 0 NA
KDQ: physical 4 1.20 0.88–1.52 0.2
KDQ: fatigue 4 0.79 0.49–1.09 0.6
KDQ: relationships 4 0.45 0.19–0.71 0.6
KDQ: depression 4 0.40 0.10–0.70 0.8
KDQ: frustration 4 0.19 −0.12–0.49 0.8
KDQ: global physical 2 0.65 0.31–0.99 0.8
KDQ: global emotional 2 0.29 −0.04–0.63 0.6
SIP: global 2 −6.55 −4.10–−5.24 <0.001
SIP: physical 2 −3.85 −4.24–−3.46 0.8
SIP: psychologic 2 −8.85 −9.93–−7.77 0.07
Abbreviations are: KDQ, Kidney Disease Questionnaire; KPS, Karnofsky Performance Scale; SIP, Sickness Impact Profile; NA, not applicable/calculable.
aTest of homogeneity; P < 0.05 = significant.
Table 6. Effects of patient clinical and experimental factors on
changes in selected study variables
Outcome Clinical/experimental factor(s)
Hemoglobin No effect
Hematocrit Year (negative, P = 0.006)
KPS Year (negative, P < 0.001)
SIP: global scale Year (positive, P = 0.02)
SIP: physical scale Year (positive, P < 0.001), experimental
design (negative, P < 0.001), disease
duration (positive, P < 0.001)
SIP: psychologic scale Year (positive, P < 0.001), experimental
design (negative, P < 0.001)
OR for transfusions Age (positive, P < 0.001), iron use
(positive, P = 0.001)
Abbreviations are: KPS, Karnofsky Performance Scale; OR, odds ratio; SIP,
Sickness Impact Profile.
epoetin alfa on hospitalizations and transfusions. By ana-
lyzing available data for these variables, we have demon-
strated that epoetin alfa therapy for anemic patients with
chronic renal failure is beneficial for the patient and the
health care system.
In every study that has been included in this meta-
analysis, epoetin alfa treatment was associated with im-
provements in patients’ clinical state and well-being and
with reductions in transfusions. Reductions in hospital-
ization were associated with epoetin alfa treatment in all
studies but one (Powe et al [18]), in which a very small pos-
itive odds ratio indicated increased odds of hospitaliza-
tion. This study did not present a stand-alone clinical trial,
and found greater-than-average hospitalization rates in
comparison to the other studies in the meta-analysis; no-
tably, it also found significant decreases in readmissions,
hospital days, and overall hospital costs per patient.
The increase in hemoglobin/hematocrit levels after
epoetin alfa administration was striking, at 40% to 50%
relative to baseline scores, across all the studies included
in the meta-analysis. We predicted corresponding sub-
stantial improvements in quality-of-life and capacity to
undertake activities of daily living. As anticipated, the
positive response in reduced anemia was matched by pos-
itive responses in all quality-of-life measures. The extent
of quality-of-life change relative to baseline was univer-
sally positive, varying across studies from approximately
10% (KPS) to about 70% (SIP psychologic subscale).
Across studies, the hospitalization rate for patients who
received epoetin alfa therapy was substantially lowered
relative to the pretreatment period, as was the number
of days of hospitalization (length of stay) per patient. In
addition, both the transfusion rate and the total number
of blood units transfused were substantially reduced.
Strong evidence was seen in favor of a benefit from
epoetin alfa therapy in reducing the use of hospitaliza-
tions and transfusions. Several studies suggest that net
costs are reduced with use of epoetin alfa therapy com-
pared with non-use [17]: patients on epoetin alfa therapy
require fewer transfusions [8] and fewer hospital admis-
sions [18], and mortality and morbidity associated with
epoetin alfa therapy have been consistently reported as
low to nonexistent [7, 18]. These results are in keeping
with a recent analysis showing that, among patients re-
ceiving hemodialysis, the number of hospitalizations and
length of stay both decrease as hemoglobin levels increase
[28]. The overall cost of transfusion has increased in re-
cent years along with cost per unit of transfused blood,
documented blood supply shortages, and newly imple-
mented safety procedures (e.g., leukodepletion), as well
as rising acquisition, storage, and administration costs
[29, 30]. Meanwhile, the cost and the recommended dose
of epoetin alfa for this patient population have both
decreased substantially [31]. While a comprehensive
analysis of overall cost of care is beyond the scope of
this report, the costs associated with hospitalizations and
transfusions presently constitute two of the most impor-
tant elements of resource utilization for patients with
chronic renal failure, and any reduction in hospitaliza-
tions and transfusions seems likely to lead to an overall
lower cost of patient care.
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Fig. 5. Impact of study’s year of publication on changes in hematocrit
(A) level, Karnofsky Performance Scale (KPS) score (B), and Sick-
ness Impact Profile (SIP) global scale score (C) following epoetin alfa
therapy.
It should be noted that in many of the studies used
in this analysis, the mean baseline hemoglobin level was
lower than that generally seen among patients in whom
epoetin alfa therapy would normally be initiated now,
raising a question as to whether conclusions generalized
from these results remain relevant for present purposes.
While anemia in patients with chronic renal failure is be-
ing treated more aggressively now that epoetin alfa is
widely available, trends suggest that a considerable frac-
tion of patients entering dialysis still have significantly
lower hematocrit levels than are specified by the recom-
mended targets, with those receiving predialysis erythro-
poietic therapy having a higher hematocrit at initiation
of dialysis than those left untreated [32]. Given that
the hemodialysis population reductions in hospitalization
continue to appear for incremental increases in hemoglo-
bin levels as high as 13 g/dL (P < .0001 for ≥13 g/dL vs.
≤11 but >12 g/dL) [28], it is probable that the potential
benefits of optimizing the management of anemia in pa-
tients with chronic renal failure have not yet reached a
plateau.
The advantages of contemporary meta-analysis include
the abilities to elucidate the relationships between vari-
ables; increase statistical power by integrating evidence
from numerous diverse international studies; detect and
explain bias and heterogeneity; identify deficiencies in
the design of past and current studies; and generate
fruitful new directions for research [33–36]. This meta-
analysis has demonstrated consistency of findings across
the studies reviewed, despite the fact that these studies
differed both in design and in extent of benefit ob-
served. Where statistically significant between-study vari-
ance was found, analyses were undertaken to identify
possible sources of this variation. Overall, randomized,
controlled trials showed epoetin alfa to have a greater
positive effect on quality of life than uncontrolled trials.
A sensitivity analysis examining the response to epoetin
alfa using only data from randomized controlled trials
generated efficacy estimates similar to those arrived at
by the overall meta-analysis. Notably, while randomized
controlled trials represent the gold standard for assess-
ing potential efficacy, the inclusion of uncontrolled trials
may ultimately yield better estimates of real-world effi-
cacy. Potential biases and discrepancies, of course, exist
within all sorts of individual clinical trials, as well as within
meta-analyses [37]. Clinicians must ultimately interpret
all reports with caution, since both large randomized con-
trolled trials and meta-analyses report population effects
rather than instructing how to treat the individual patient
[38].
The present analysis clearly points toward a consensus
in favor of an overall hematologic and quality-of-life ben-
efit, plus reductions in hospitalizations and transfusions,
for epoetin alfa therapy in anemic patients with chronic
renal failure. Additional rigorously controlled, random-
ized trials, consciously designed to avoid biases and dis-
crepancies, are, as always, desirable to corroborate and
substantiate these meta-analytically derived conclusions.
CONCLUSION
Overall, results from this meta-analysis strongly sug-
gest that for patients with anemia associated with chronic
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renal failure, epoetin alfa increases hemoglobin and
hematocrit levels, with resulting significant and substan-
tial improvements in quality-of-life. In addition, there
were major decreases in hospitalizations and transfusions
for patients who were treated with epoetin alfa. Further
study, using both naturalistic and randomized, controlled
designs, should be conducted to investigate and corrobo-
rate these relationships.
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